Current Clinical Trials

Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lash MD, Bradley
Sponsor: ALLIANCE
Indentifier #: NCT01841736
Title: Alliance A021202, Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients With Progressive Carcinoid Tumors; ClinicalTrials.gov identifier: NCT01841736
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: Celldex
Indentifier #: NCT01997333
Title: CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Genentech
Indentifier #: NCT01615068
Title: Genentech ML 28257; An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SWOG
Indentifier #: NCT01674140
Title: S1207, Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Lash MD, Bradley
Sponsor: SWOG
Indentifier #: NCT02154490
Title: S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sponsor: ALLIANCE
Indentifier #: NCT01835158
Title: Alliance A031203,Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Sponsor: Pfizer
Indentifier #: NCT01968967
Title: B1481020, A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS – SPIRE LDL
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: NSABP
Indentifier #: NCT00769379
Title: NSABP B43, A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: SCUSF
Indentifier #: NCT01009918
Title: SCUSF-0806, Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: ALLIANCE
Indentifier #: NCT01573442
Title: Alliance A221102, Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias